DIMENSION®

Additional Manufacturer Narrative

ADDITIONAL INFORMATION (09-JUN-2023): SIEMENS HEALTHCARE DIAGNOSTICS HEADQUARTERS SUPPORT CENTER (HSC) AND TECHNICAL OPERATIONS (TECHOPS) CONCLUDED THE INVESTIGATION OF THE EVENT. HSC REVIEWED THE ATTACHMENT (PHOTO) AND THE INFORMATION PROVIDED BY THE CUSTOMER. THE ATTACHMENT SHOWED THAT THE CHROMIUM OXIDE (CRO2) TABLET WAS ATTACHED TO THE TOP OF THE FLEX FILM AND DID NOT HYDRATE. THE TABLET BEING ATTACHED TO THE TOP OF FLEX FILM COULD PREVENT THE REACTION FROM COMPLETING. SIEMENS HEALTHCARE DIAGNOSTICS TECHOPS REVIEWED THE INFORMATION PROVIDED AND CONCLUDED THAT A PRODUCT NON-CONFORMANCE WAS NOT IDENTIFIED WITH THE CSA ASSAY OR THE DIMENSION EXL 200 SYSTEM. THE EVENT IS CONSISTENT WITH A TABLET HYDRATION ISSUE. THE CAUSE OF THE EVENT IS UNKNOWN. A POTENTIAL PRODUCT ISSUE WAS NOT IDENTIFIED. THE CUSTOMER IS OPERATIONAL. THE DEVICE IS PERFORMING WITHIN SPECIFICATIONS. NO FURTHER EVALUATION IS REQUIRED. SECTION H6 HAS BEEN UPDATED TO REFLECT THE SIEMENS INVESTIGATION. INITIAL MDR 2432235-2023-00132 WAS FILED ON 02-JUN-2023.

Description of Event or Problem

TWO (2) DISCORDANT FALSELY ELEVATED CYCLOSPORINE A (CSA) RESULTS WERE OBTAINED ON A PATIENT SAMPLE ON A DIMENSION EXL 200 SYSTEM. ONE OF THE FALSELY ELEVATED RESULTS WAS REPORTED TO THE PHYSICIAN(S), AND THE RESULT WAS QUESTIONED. THE SAME SAMPLE WAS REPROCESSED ON AN ALTERNATE DIMENSION EXL 200 SYSTEM, AND THE REPROCESSED RESULT WAS CONSIDERED CORRECT. A CORRECTED REPORT WAS ISSUED. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE FALSELY ELEVATED CYCLOSPORINE A (CSA) RESULTS.

Additional Manufacturer Narrative

AN OUTSIDE OF THE UNITED STATES (OUS) CUSTOMER CONTACTED THE SIEMENS HEALTHCARE DIAGNOSTICS REMOTE SERVICES CENTER (RSC) REGARDING TWO (2) FALSELY ELEVATED CYCLOSPORINE A (CSA) PATIENT SAMPLE RESULTS OBTAINED ON A DIMENSION EXL 200 SYSTEM. SIEMENS IS INVESTIGATING THE EVENT.